[1] Tao H, Li F, Li R, et al. Successful treatment of a patient with non-small cell lung cancer and interstitial lung disease with durvalumab: a case report[J]. Ann Palliat Med, 2020, 9(5): 3623-3628. DOI: 10.21037/apm-20- 1134.
[2] Tonk EHJ, van Lindert ASR, Verhoeff JJC, et al. Acute-onset pneumonitis while administering the first dose of durvalumab[J]. Case Rep Oncol, 2019, 12(2):621-624. DOI: 10.1159/000502202.
[3] Singh V, Chu Y, Gupta V, et al. A tale of immune-related adverse events with sequential trials of checkpoint inhibitors in a patient with metastatic renal cell carcinoma[J]. Cureus, 2020, 12(6): e8395. DOI: 10.7759/cureus.8395.
[4] Kato Y, Watanabe Y, Yamane Y, et al. Reactivation of TB during administration of durvalumab after chemoradiotherapy for non-small-cell lung cancer: a case report[J]. Immunotherapy, 2020, 12(6):373-378. DOI: 10.2217/imt-2020-0061.
[5] Terashima T, Iwami E, Shimada T, et al. IgG4-related pleural disease in a patient with pulmonary adenocarcinoma under durvalumab treatment: a case report[J]. BMC Pulm Med, 2020, 20(1): 104. DOI: 10.1186/s12890-020-1150-x.
[6] Rousseau PM, Raimbourg J, Robert M, et al. First case of cutaneous sarcoidosis within tattoos under durvalumab[J]. Int J Dermatol, 2019, 58(9): e168-e170. DOI: 10.1111/ijd.14484.
[7] Pringle S, van der Vegt B, Wang X, et al. Lack of conventional acinar cells in parotid salivary gland of patient taking an anti-PD-L1 immune checkpoint inhibitor[J]. Front Oncol, 2020, 10:420. DOI: 10.3389/fonc.2020.00420.
[8] Utsumi T, Tsubouchi K, Harada T. Refractory severe esophagitis during durvalumab therapy in a patient with locally advanced NSCLC[J]. J Thorac Oncol, 2019, 14(2):e40-e42. DOI: 10.1016/j.jtho.2018.10.153.
[9] Mahmood SS, Chen CL, Shapnik N, et al. Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: a case report[J]. Gynecol Oncol Rep, 2018, 25:74-77. DOI: 10.1016/j.gore.2018.05.014.
[10] Carrera W, Baartman BJ, Kosmorsky G. A case report of drug-induced myopathy involving extraocular muscles after combination therapy with tremelimumab and durvalumab for non-small cell lung cancer[J]. Neuroophthalmology, 2017, 41(3):140-143. DOI: 10.1080/01658107.2017.1291686.
[11] 焦秀秀,李艳,沈波, 等.度伐利尤单抗致急性间质性肾炎的病例报道并文献分析[J].药学服务与研究,2022,22(01):75-78.
[12] 梁瑜,孟真,周长凯, 等.度伐利尤单抗致重度免疫相关性肝炎1例[J].中国医院药学杂志,2022,42(1):107-108.DOI:10.13286/j.1001-5213.2022.01.21.
[13] Sabini E, Sframeli A, Marinò M. A case of drug-induced Graves' Orbitopathy after combination therapy with Tremelimumab and Durvalumab[J]. J Endocrinol Invest, 2018, 41(7):877-878. DOI: 10.1007/s40618-018-0906-0.
[14] Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-45. DOI: 10.1038/clpt.1981.154.
|
